Download PDF
Thromb Haemost 1996; 75(02): 286-291
DOI: 10.1055/s-0038-1650262
Original Article
Schattauer GmbH Stuttgart

Low Molecular Weight Heparin Is Responsible for the Anti-Xa Activity of Desmin 370

David Brieger
1   The Applied Research Group, The Heart Research Institute, Sydney, Australia
,
Joan Dawes
1   The Applied Research Group, The Heart Research Institute, Sydney, Australia
2   The CRC for Biopharmaceutical Research, Darlinghurst, NSW, Australia
› Author Affiliations
Further Information

Publication History

Received 07 June 1995

Accepted after resubmission 07 November 1995

Publication Date:
26 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Dermatan sulphate does not catalyse the inactivation of factor Xa. However, the low molecular weight (LMW) dermatan sulphate Desmin 370 has been shown to generate circulating anti-Xa activity following administration to humans. Using a single batch of Desmin 370, we measured 3 U/mg of anti-Xa activity by amidolytic assay in vitro. The material responsible for this activity had a lower molecular weight range (6000 and 1800 Da) than Desmin 370 and was more highly sulphated than the bulk of the drug. Heparinase digestion of Desmin 370 eliminated 90% of the in vitro anti-Xa activity without significantly interfering with its ability to potentiate inactivation of thrombin by HCII, suggesting that the anti-Xa activity is not due to dermatan sulphate and is probably heparin. When 125I-labelled Desmin 370 together with 40 mg/kg carrier drug was administered intravenously to a rabbit, anti-Xa activity was readily detectable in the plasma for up to 10 h and had a longer half-life than the sulphated radiolabel. Most of this anticoagulant activity was recovered from the plasma by Polybrene affinity chromatography and was probably a sulphated glycosaminoglycan. Administration of the heparinase-digested drug to a rabbit resulted in 70% less anti-Xa activity than the undigested drug. We conclude that Desmin 370 contains detectable quantities of biologically active low molecular weight heparin, which is responsible for persistent anti-Xa activity following intravenous administration.

 

  • References

  • 1 Tollefsen D, Pestka C, Monafo W. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6773-6776
    PubMedSearch in Google Scholar
  • 2 Ofosu F, Modi G, Smith L, Cerskus A, Hirsh J, Blajchman M. Heparin sulphate and dermatan sulphate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
    PubMedSearch in Google Scholar
  • 3 Buchanan M, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedSearch in Google Scholar
  • 4 Fernandez F, Van Ryn J, Ofosu F, Hirsh J, Buchanan M. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317
    CrossrefPubMedSearch in Google Scholar
  • 5 Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-335
    PubMedSearch in Google Scholar
  • 6 Merton R, Thomas D. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemost 1987; 58: 839-842
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Prandoni P, Meduri F, Cuppini S, Toniato A, Zangrandi F, Polistena P, Gianese F, Maffei Faccioli A. Dermatan sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-509
    CrossrefPubMedSearch in Google Scholar
  • 8 Lane D, Ryan K, Ireland H, Curtis J, Nurmohamed M, Krediet R, Roggekamp M, Stevens P, ten Cate J. Dermatan sulfate in haemodialysis. Lancet 1992; 339: 334-335
    CrossrefPubMedSearch in Google Scholar
  • 9 Agnelli G, Cosmi B, Di Filippo P, Ranucci V, Veschi F, Longetti M, Régna C, Barzi F, Gianese F, Lupattelli L, Rinonapoli E, Nenci G. A randomised, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 647: 203-208
    PubMedSearch in Google Scholar
  • 10 van Ryn-McKenna J, Gray E, Weber E, Ofosu F, Buchanan M. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 1989; 61: 7-9
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 van Ryn-McKenna J, Ofosu F, Gray E, Hirsh J, Buchanan M. Effects of dermatan sulphate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 1989; 556: 304-312
    CrossrefPubMedSearch in Google Scholar
  • 12 Dol F, Houin G, Rostin M, Montastruc J, Dupouy D, Gianese F, Sié P, Boneu B. Pharmacodynamics and pharmacokinetics of dermatan sulphate in humans. Blood 1989; 74: 1577-1582
    PubMedSearch in Google Scholar
  • 13 Dawes J, Hodson B, MacGregor I, Pepper D, Prowse C. Pharmacokinetic and biological activities of dermatan sulphate (Mediolanum MF701) in healthy human volunteers. Ann N Y Acad Sci 1989; 556: 292-303
    CrossrefPubMedSearch in Google Scholar
  • 14 Dol F, Petitou M, Lormeau J, Choay J, Caranobe C, Sié P, Saivin S, Houin G, Boneu B. Pharmacologic properties of a low molecular weight dermatan sulphate: Comparison with unfractionated dermatan sulphate. J Lab Clin Med 1989; 115: 43-51
    PubMedSearch in Google Scholar
  • 15 Saivin S, Sol F, Caranobe C, Petitou M, Lormeau J, Sié P, Houin G, Boneu B. Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit. Thromb Res 1992; 66: 527-535
    CrossrefPubMedSearch in Google Scholar
  • 16 Dawes J. The pharmacokinetics of LMW dermatan sulphate: long term persistence of intact material. Thromb Haemost 1993; 69: 339-343
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Cucinotta D, Manopulo R, Galanti M, Zamboni V, Palazzini E, Barbanti M, Milani M. Pharmacodynamics of a new low-molecular-weight dermatan sulfate after a single subcutaneous injection on elderly patients with chronic venous disorders: a phase 1 trial. Curr Ther Res 1994; 55: 1492-1500
    CrossrefPubMedSearch in Google Scholar
  • 18 Dettori A, Galli G, Manotti C, Palazzini E. Pharmacological activity of a low molecular weight dermatan sulfate (Desmin) in healthy volunteers. Semin Thromb Haemost 1994; 20: 259-265
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Mascellani G, Bianchini P. European Patent 1990, No 0221977;. USA Patent 1990, No 4973580
    PubMed
  • 20 Barbanti M, Calanni F, Milani M, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis - evidence for an anticoagulant-independent mechanism. Thromb Haemost 1993; 69: 147-151
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Barbanti M, Calanni F, Babbini M, Bergonzini G, Parma B, Marchi E. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res 1993; 71: 417-422
    CrossrefPubMedSearch in Google Scholar
  • 22 Abbadini M, Zhu G, Maggi A, Pangrazzi J, Donati M, Mussoni L. Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. Blood 1987; 70: 1858-1860
    PubMedSearch in Google Scholar
  • 23 Legnani C, Palareti G, Biagi R, Ludovici S, Maggiore L, Milani M, Coccheri S. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects. Eur J Clin Pharmacol 1994; 47: 247-252
    CrossrefPubMedSearch in Google Scholar
  • 24 Bergonzini G, Bianchini P, Hoppensteadt D, Parma B, Osmi B, Walenga J, Fareed J. Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates. Semin Thromb Haemost 1991; 17: 235-239
    PubMedSearch in Google Scholar
  • 25 Thomas DP, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
    CrossrefPubMedSearch in Google Scholar
  • 26 Thomas D, Lane D, Michalski R, Johnson E, Kakkar V. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
    PubMedSearch in Google Scholar
  • 27 Harenberg J, Stehle G, Dempfle C-E, Schafer M, Giese C. Evidence of a specific heparin binding site of tissue factor pathway inhibitor for different glycosaminoglycans. Thromb Haemost 1993; 69: 861
    PubMedSearch in Google Scholar
  • 28 Dawes J, Pepper D. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
    CrossrefPubMedSearch in Google Scholar
  • 29 Dawes J, Prowse C, Pepper D. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemost 1985; 54: 630-634
    Thieme ConnectPubMedSearch in Google Scholar
  • 30 Lam L, Silbert J, Rosenberg R. The separation of active and inactive forms of heparin. Biochem Biophys Res Comm 1976; 69: 570-577
    CrossrefPubMedSearch in Google Scholar
  • 31 Greenwood F, Hunter W, Glover J. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-123
    PubMedSearch in Google Scholar
  • 32 Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulphate and dermatan sulphate. Thromb Res 1976; 8: 859-867
    CrossrefPubMedSearch in Google Scholar
  • 33 Brieger D, Dawes J. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane). Thromb Haemost 1994; 72: 275-280
    Thieme ConnectPubMedSearch in Google Scholar
  • 34 Zammit A, Dawes J. Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulfate. Blood 1995; 85: 720-726
    PubMedSearch in Google Scholar
  • 35 Hodson B, Pepper D, Dawes J. Novel affinity chromatographic system for the single step purification of glycosaminoglycans from complex systems using volatile buffers. J Chromatog 1991; 565: 416-423
    CrossrefPubMedSearch in Google Scholar
  • 36 Maimone M, Tollefsen D. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem 1990; 265: 18263-18271
    PubMedSearch in Google Scholar
  • 37 Dawes J, Pepper DS. Catabolism of low dose heparin in man. Thromb Res 1979; 14: 845-860
    CrossrefPubMedSearch in Google Scholar
  • 38 MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulphate in man - catabolism of iodinated derivatives. Thromb Haemost 51: 321-325
    PubMed
  • 39 Barrowcliffe TW, Johnson EA, Thomas DP. Low Molecular Weight Heparin. John Wiley and Sons; Chichester, New York, Brisbane, Toronto, Singapore: 1992
    Search in Google Scholar
  • 40 Briant L, Caranobe C, Saivin S, Sie P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and Ha effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-353
    Thieme ConnectPubMedSearch in Google Scholar
  • 41 Lindahl A, Abildgaard U, Larsen M, Aamodt L-M, Nordfang O, Beck T. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res 1991; Suppl XIV 39-48
    PubMedSearch in Google Scholar
  • 42 Blajchman M, Young E, Ofosu F. Effects of unfractionated heparin, dermatan sulphate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989; 556: 245-254
    CrossrefPubMedSearch in Google Scholar
  • 43 Lohse D, Lindhardt R. Purification and characterisation of heparin lyases from flavobacterium heparinum. J Biol Chem 1992; 267: 24347-24355
    PubMedSearch in Google Scholar
  • 44 Kindness G, Long W, Williamson F. The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III. Br J Pharmac 1981; 72: 81-88
    CrossrefPubMedSearch in Google Scholar
  • 45 Thomas D, Gray E, Merton R. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin. Thromb Haemost 1990; 64: 290-293
    Thieme ConnectPubMedSearch in Google Scholar
  • 46 Cadroy Y, Dol F, Caranobe C, Petitou M, Lormeau J, Sié P, Choay J, Boneu B. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not. Thromb Haemost 1988; 59: 295-298
    Thieme ConnectPubMedSearch in Google Scholar
  • 47 Caranobe C, Gabaig A, Sié P, Boneu B. Antithrombotic effects of the association standard heparin-dermatan sulphate. Thromb Haemost 1991; 65: 107
    Thieme ConnectPubMedSearch in Google Scholar